Issue Highlights

Clinical Trial Update
The 3-year data have shown us a continued, highly significant statistically but also very clinically meaningful difference in the outcomes of target vessel-related myocardial infarction, target…
Dr. Kandzari, you presented BIOFLOW V results at the CRT meeting in late February of this year. We last spoke about the Orsiro stent (Biotronik) in 2019, when the 2-year results were available.1 How do the 3-year results now compare? As part of the trial, we have planned…